The panelists make the point that (1):
. . . some diseases do not have a uniformly static expression and may evolve, as a consequence of remodeling, from one category to another during their natural clinical course; eg, hypertrophic cardiomyopathy, amyloid, and other infiltrative conditions may progress from a nondilated (often hyperdynamic) state with ventricular stiffness to a dilated form with systolic dysfunction and failure.
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Etiologies of cardiomyopathy include one or more of the following: genetics (about 20% of patients with idiopathic dilated cardiomyopathy have a relative with decreased ejection fraction), inflammation, infection, post-partum state, tachycardia, exposure to cardiotoxic agents (e.g., mediastinal radiation, chemotherapy with agents like doxorubicin or antibody therapy with trastuzumab), consumption of alcohol, and idiopathic causes (2) . Regardless of etiology, injury to the myocardium impairs myocardial contractility, resulting in heart failure.
Dilated cardiomyopathy accounts for ϳ25% of patients with heart failure in the United States (3). Patients with dilated cardiomyopathy in heart failure have a mortality ranging from 10% to 50%/yr (4). Patients with a treatable etiology often have a good prognosis for stabilization or improvement in function. In contrast, patients without a defined etiology are at risk of progressive disease. Decreased systolic function is usually treated with medical therapy (5).
In patients with left ventricular ejection fraction (LVEF) Ͻ35% or wide QRS complexes, either resynchronization therapy or an implanted cardiac defibrillator may be necessary. Despite therapy, some patients have progressive heart failure requiring a heart transplant.
A universal manifestation of cardiomyopathy is a decrease in contractile performance. Cardiac histopathology demonstrates marked alterations in the appearance of the contractile apparatus and in the appearance and location of mitochondria within the myocyte. A study of explanted hearts of patients with dilated myopathy undergoing transplantation demonstrated that "mitochondria occurred in large clusters in cytoplasm free of myofibrils, and they varied in size and shape from very small to very large. [There was a] lack of myofibrils in many cellular areas, in the center and in the periphery of a myocyte. Next to hypertrophied cells, other cells were atrophic" (6) .
This appearance suggests that the mitochondria could not transfer high-energy phosphate efficiently, even if the mitochondria were working normally. As a result, assessing mitochondrial function could provide information about the performance of the heart as a muscle.
Myocardial mitochondria have the daunting task of producing about 30 kg/d of adenosine triphosphate (ATP) to maintain function (7). To meet this demand there must be continuous delivery of substrate to the mitochondria, the mitochondria must have adequate oxidative capacity, and the cell must have an effective transfer system of ATP from the mitochondria to sites of utilization (8) . Based on the histopathology of the explanted hearts, it is likely that both the energy-producing and energy-transfer components of mitochondria cannot function normally in the myopathic heart.
One parameter that reflects mitochondrial function is the transmembrane potential (TMP) of the mitochondria (9) . Under normal circumstances, mitochondria have the most electronegative potential of the organelles in the myocyte and therefore are the site of localization of charged lipophilic molecules that pass through the sarcolemma. Retention of these agents in the cell is proportional to TMP, and loss of TMP results in loss of the indicator. In vitro, multiple dyes can be used to determine mitochondrial function; in vivo, the choices are more limited.
The lipophilic cationic myocardial perfusion agent, technetium-99m methoxyisobutylisonitrile (MIBI) localizes primarily in mitochondria (10) . The positively charged fat-soluble molecule traverses the myocardial sarcolemma, enters the cell, and localizes in the highly electronegative mitochondria. MIBI is retained in the mitochondria by the higher membrane potential. Loss of mitochondrial membrane potential results in rapid loss of MIBI from the myocyte (11, 12) . Investigators have tested the relationships of MIBI washout to mechanical dysfunction and prognosis.
Matsuo et al. (13) evaluated 61 patients with nonischemic congestive heart failure. The myocardial washout rate (WR), calculated from planar images, correlated with the level of B-type naturetic peptide, increased with increasing New York Heart Association class and correlated negatively with LVEF. Over a mean follow-up of 12 months (range: 1 to 19 months), patients with a WR Ն28% had more events than did subjects with lower WR. Isobe et al. (14) studied 24 patients with hypertrophic myopathy. The investigators recorded planar and single-photon emission computed tomographic MIBI images following injection at rest. The heart-to-mediastinal ratio was calculated from planar images recorded at 40 min and at 4 h. The investigators found increased MIBI loss from the myocardium in patients with elevated left ventricular end-diastolic pressure and prolonged half-time of relaxation. In 17 patients with dilated cardiomyopathy (mean LVEF: 29%), Shiroodi et al. (15) measured MIBI washout and compared the results to those from 6 normal subjects (mean LVEF: 66%). The investigators acquired images at 30 min and 3.5 h after injection. Regions of interest placed in the mediastinum and the entire LV myocardium on an anterior planar view were used to determine the washout in the 3-h interval between images. Cardiomyopathy patients had a WR of 29.13 versus 14.17 for controls. WRs increased from 23.16 for patients with NYHA class I, 30.25 for class II, 32.60 for class III, and 37.5 for class IV. WR was negatively correlated with LVEF (r 2 ϭ 0.679). In this issue of the Journal, Hayashi et al. (16) add significant information to these observations. The investigators studied 20 patients with dilated cardiomyopathy (NYHA class I, n ϭ 8; class II, n ϭ 10; and class III, n ϭ 2; mean LVEF: 33%). The myopathy patients did not have a history of coronary disease, valvular disease, hypertension, chronic atrial fibrillation, or diabetes. All myopathy subjects had cardiac catheterization with coronary angiography, dobutamine infusion to detect changes in maximum first derivative of LV pressure (LV dP/dt max ), endocardial biopsy (to exclude myocarditis), and reverse transcriptase-polymerase chain reaction (RT-PCR) of the biopsy specimen; 6 subjects had electron microscopy of the biopsy specimen. The electron microscopy specimens had quantitation of the number and size of mitochondria and the severity of mitochondrial degeneration.
Hayashi et al. (16) used a slightly different protocol than did Shiroodi et al. (15) , recording MIBI images at 1 and 4 h after injection. Myocardial retention of MIBI was measured on planar images as: (initial net myocardial counts* -delayed net myocardial counts † )/initial net myocardial counts. Despite minor differences in technique, the results were similar. Overall, Matsuo, Isobe, Shiroodi, and Hayashi found a decrease in myocardial MIBI retention in myopathy patients compared with those in control patients.
Hayashi divided the myopathy patients into two groups based on the WR. The group with a greater WR had a reduction in the abundance of mRNAs for mitochondrial electron transport-related enzymes on RT-PCR and more extensive mitochondrial damage on electron microscopy.
Although the number of subjects was small, the data suggest that adding a simple measurement to a myocardial perfusion scan can provide information about mitochondrial status. As stated by Ventura-Clapier et al. (8) , "Despite the diversity of origin and of clinical manifestation of heart failure, defects in energy metabolism are increasingly considered as an important determinant in the progression of the disease." Hayashi et al. (16) have done an excellent job demonstrating the anatomic and functional correlation of the MIBI WR. Now it is up to the Nuclear Cardiology community to utilize this additional measurement, to define its role in patient management.
